Yeah, I just read this on the annual report
Seqirus sales of US$652 million reflect 11 months of sales since
the acquisition of Novartis’ influenza vaccines business on 31
July 2015. Sales of influenza vaccine were adversely impacted by
a mild influenza season in the northern hemisphere. The Seqirus
business turnaround program remains on track.
CSL Decline, page-35
-
- There are more pages in this discussion • 158 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$309.72 |
Change
0.430(0.14%) |
Mkt cap ! $149.6B | |||
| Open | High | Low | Value | Volume |
| $310.10 | $311.54 | $308.61 | $295.6M | 953.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 8 | 14819 | $309.72 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $310.00 | 36 | 1 |
View Market Depth
| Last trade - 16.10pm 31/07/2024 (20 minute delay) ? |
| CSL (ASX) Chart |